Aromatic Heterocyclic Crystal Forms for Stable JAK Inhibitor Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing aromatic heterocyclic compounds used as JAK kinase inhibitors face issues with drug polymorphism affecting stability, absorption, and bioavailability, leading to inconsistent clinical efficacy due to variations in crystal forms.
Innovation Solution
Development of specific crystal forms (I, III) of the aromatic heterocyclic compound with characteristic X-ray diffraction peaks, demonstrating stability and anhydrous nature, suitable for pharmaceutical applications, and a production method involving solvents like water and ethanol to maintain stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aromatic heterocyclic compounds are used as JAK kinase inhibitors, then therapeutic activity against autoimmune and inflammatory diseases is achieved, but drug polymorphism causes inconsistent stability, absorption, and bioavailability
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing specific crystal forms (Forms I, II, III) with distinct X-ray diffraction patterns and physical properties. By establishing precise diffraction peak parameters (2θ angles at 7.9°, 9.4°, 15.7°, 19.2° for Form I; 8.1°, 9.6° for Form II; 8.4°, 10.0°, 13.6°, 16.4°, 19.7° for Form III), the patent transforms the polymorphism issue into a controllable parameter-based system where specific crystal forms can be selected and maintained for consistent drug performance.
Solution Approach 2:
The patent applies preliminary action by providing advance characterization and classification of different crystal forms before clinical use. The detailed X-ray diffraction data, melting point ranges, and stability profiles of each crystal form are established beforehand, enabling manufacturers to select the optimal crystal form (particularly Form I with superior stability) before production and storage, thereby preventing efficacy inconsistency from the outset.
2Adaptability or versatility
If different crystal forms of the aromatic heterocyclic compound are used, then variations in physical properties occur, but this leads to inconsistent absorption and bioavailability
Solution Approach 1:
The patent resolves this contradiction by establishing precise physical parameter ranges for each crystal form. Form I is characterized by melting point 198-202°C and specific diffraction peaks, while Form II melts at 200-204°C and Form III at 194-198°C. These parameter definitions enable manufacturers to control crystal form selection through temperature and processing conditions, achieving both formulation flexibility and manufacturing precision.
Solution Approach 2:
The patent applies preliminary action by providing advance guidance on obtaining and maintaining specific crystal forms. The patent describes methods to produce Form I (the most stable form) and establishes storage conditions that prevent transformation to other forms. This preliminary characterization enables consistent manufacturing and storage practices that maintain crystal form integrity throughout the pharmaceutical lifecycle.
3Duration of action of stationary object
If crystal transformation occurs during storage, then drug stability deteriorates, but this affects clinical efficacy
Solution Approach 1:
The patent applies preliminary action by pre-characterizing the stability profiles of different crystal forms and establishing storage conditions that prevent transformation. Form I is identified as the most stable form with defined storage parameters. By establishing these stability profiles beforehand, the patent enables long-term storage without crystal transformation, maintaining both storage stability and clinical efficacy over extended periods.
Solution Approach 2:
The patent resolves this contradiction by establishing temperature and environmental parameter ranges that prevent crystal transformation during storage. By defining the stable parameter ranges for Form I (melting point 198-202°C, specific humidity and temperature conditions), the patent ensures that storage conditions remain within boundaries that maintain crystal form integrity, thereby preserving both storage stability and clinical efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms I and III exhibit enhanced stability and consistency, preventing crystal transformation during storage and pharmaceutical processing, ensuring reliable clinical efficacy as JAK kinase inhibitors for autoimmune diseases, inflammatory diseases, and cancer treatment.
Implementation Method 1
The crystal form I of an aromatic heterocyclic compound, using X-ray diffraction, has characteristic diffraction peaks at 2θ angles of 8.4°, 10.0°, 13.6°, 16.4°, and 19.7°
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The present disclosure provides a crystal form of aromatic heterocyclic compound, composition thereof, production method thereof and uses thereof. The crystal forms include: crystal form I and crystal form III, using X-ray diffraction method to have characteristic diffraction peaks at about 8.4°, 10.0°, 13.6°, 16.4°, and 19.7°, respectively; and at about 8.2°, 9.8°, 17.2°, and 26.8°; the aromatic heterocyclic compound is added with a suitable solvent for stirring, filtering, and drying to obtain crystal form I or III; and the use of crystal form I or crystal form III in the production of drugs for preventing or treating diseases caused by abnormal JAK-STAT signaling pathways. It can be used for autoimmune diseases, cancer, and myeloproliferative diseases.